CL2008003524A1 - Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia. - Google Patents
Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia.Info
- Publication number
- CL2008003524A1 CL2008003524A1 CL2008003524A CL2008003524A CL2008003524A1 CL 2008003524 A1 CL2008003524 A1 CL 2008003524A1 CL 2008003524 A CL2008003524 A CL 2008003524A CL 2008003524 A CL2008003524 A CL 2008003524A CL 2008003524 A1 CL2008003524 A1 CL 2008003524A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- rheumatoid
- disease
- pkr
- anorexia
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 206010037660 Pyrexia Diseases 0.000 title abstract 2
- 206010040047 Sepsis Diseases 0.000 title abstract 2
- 208000022531 anorexia Diseases 0.000 title abstract 2
- 230000001363 autoimmune Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 206010061428 decreased appetite Diseases 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
Abstract
Composición farmacéutica que comprende al menos un inhibidor de proteína quinasa dependiente de ARN de doble hebra (PKR), uso de la composición para el tratamiento de una condición seleccionada de cáncer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99013407P | 2007-11-26 | 2007-11-26 | |
US3737108P | 2008-03-18 | 2008-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003524A1 true CL2008003524A1 (es) | 2010-01-22 |
Family
ID=40099551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003524A CL2008003524A1 (es) | 2007-11-26 | 2008-11-26 | Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110077198A1 (es) |
EP (1) | EP2222297A1 (es) |
JP (1) | JP2011504879A (es) |
CN (1) | CN101868235A (es) |
AR (1) | AR069479A1 (es) |
AU (1) | AU2008329988A1 (es) |
BR (1) | BRPI0819759A2 (es) |
CA (1) | CA2706656A1 (es) |
CL (1) | CL2008003524A1 (es) |
MX (1) | MX2010005768A (es) |
RU (1) | RU2010126171A (es) |
TW (1) | TW200924744A (es) |
WO (1) | WO2009070378A1 (es) |
ZA (1) | ZA201004528B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010073104A2 (en) * | 2008-12-23 | 2010-07-01 | Carmel - Haifa University Economic Corp Ltd. | Improving cognitive function |
EP2464246A2 (en) * | 2009-08-13 | 2012-06-20 | Nestec S.A. | Nutritional compositions including exogenous nucleotides |
JP2013505720A (ja) * | 2009-09-25 | 2013-02-21 | ネステク ソシエテ アノニム | テアニン及び外因性ヌクレオチドを含む栄養組成物 |
AU2010310515B2 (en) * | 2009-10-22 | 2016-01-07 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
FR2970414B1 (fr) * | 2011-01-14 | 2013-03-22 | Univ Paris Descartes | Action preventive de la citrulline sur le developpement spontane des tumeurs |
TW201330845A (zh) * | 2011-10-18 | 2013-08-01 | Ajinomoto Kk | 胰臟癌及/或膽道癌治療劑 |
CN104039353A (zh) * | 2011-11-29 | 2014-09-10 | 贝勒医学院 | 增强认知的方法 |
CN104023715B (zh) * | 2011-12-02 | 2016-10-26 | Ea制药株式会社 | 激酶抑制剂的副作用降低剂 |
ES2822178T3 (es) | 2012-10-22 | 2021-04-29 | Univ Southern California | Formulaciones dietéticas que promueven la regeneración de tejidos/órganos |
KR101668074B1 (ko) * | 2015-02-12 | 2016-10-21 | 전북대학교산학협력단 | Pkr 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN107158388B (zh) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | MIIP pS303阻断剂在制备抗肿瘤药物中的应用 |
JP7266581B2 (ja) | 2017-08-14 | 2023-04-28 | アクセラ・ヘルス・インコーポレイテッド | 肝疾患の治療のためのアミノ酸組成物 |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2023208028A1 (zh) * | 2022-04-29 | 2023-11-02 | 中国科学院分子细胞科学卓越创新中心 | 用于治疗牛皮癣或阿尔兹海默症的具有16bp-26bp双链茎环结构的环形RNA |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06501024A (ja) * | 1991-03-29 | 1994-01-27 | アメリカ合衆国 | 皮膚腫瘍形成を予防し、存在する腫瘍の後退の原因になるための医薬組成物と方法 |
AU3982497A (en) * | 1996-07-30 | 1998-02-20 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner |
AU6336398A (en) * | 1997-02-24 | 1998-09-09 | Johns Hopkins University, The | Immunomodulatory polypeptides derived from the invariant chain of mhc class ii |
US6864061B2 (en) * | 2000-09-14 | 2005-03-08 | Genetrol Biotherapeutics, Inc. | Method for screening compounds for anti-inflammatory activity |
EP1911449A1 (en) * | 2005-07-29 | 2008-04-16 | Ltd. Torii Pharmaceutical Co. | Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
DK1957061T3 (da) * | 2005-11-30 | 2011-07-25 | Novartis Pharma Gmbh | Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind |
AU2008260572A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | IL- 18 and protein kinase R inhibition for the treatment of COPD |
-
2008
- 2008-10-03 JP JP2010534990A patent/JP2011504879A/ja active Pending
- 2008-10-03 RU RU2010126171/15A patent/RU2010126171A/ru not_active Application Discontinuation
- 2008-10-03 WO PCT/US2008/078667 patent/WO2009070378A1/en active Application Filing
- 2008-10-03 US US12/743,312 patent/US20110077198A1/en not_active Abandoned
- 2008-10-03 MX MX2010005768A patent/MX2010005768A/es not_active Application Discontinuation
- 2008-10-03 EP EP08855001A patent/EP2222297A1/en not_active Withdrawn
- 2008-10-03 CN CN200880116513A patent/CN101868235A/zh active Pending
- 2008-10-03 AU AU2008329988A patent/AU2008329988A1/en not_active Abandoned
- 2008-10-03 BR BRPI0819759-8A patent/BRPI0819759A2/pt not_active IP Right Cessation
- 2008-10-03 CA CA2706656A patent/CA2706656A1/en not_active Abandoned
- 2008-10-24 TW TW097141111A patent/TW200924744A/zh unknown
- 2008-11-25 AR ARP080105117A patent/AR069479A1/es unknown
- 2008-11-26 CL CL2008003524A patent/CL2008003524A1/es unknown
-
2010
- 2010-06-25 ZA ZA2010/04528A patent/ZA201004528B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009070378A1 (en) | 2009-06-04 |
ZA201004528B (en) | 2011-11-30 |
JP2011504879A (ja) | 2011-02-17 |
TW200924744A (en) | 2009-06-16 |
AU2008329988A1 (en) | 2009-06-04 |
AR069479A1 (es) | 2010-01-27 |
BRPI0819759A2 (pt) | 2015-05-05 |
MX2010005768A (es) | 2010-06-11 |
US20110077198A1 (en) | 2011-03-31 |
CA2706656A1 (en) | 2009-06-04 |
RU2010126171A (ru) | 2012-01-10 |
EP2222297A1 (en) | 2010-09-01 |
CN101868235A (zh) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003524A1 (es) | Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia. | |
CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
CL2009000260A1 (es) | Antagonista de pcsk9 que comprende un dominio cdr3 de la region variable de la cadena liviana y pesada, el cual inhibe la captacion celular del ldl, composicion farmaceutica que comprende dicho antagonista, uso de este, secuencia nucleotidica que codifica el antagonista, vector y celula huesped que la comprende. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
CR20120298A (es) | Antagonistas de il-17a | |
CR20110245A (es) | Mutantes fgf21 y uso de los mismos. | |
CL2008002255A1 (es) | Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf. | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
NO20080246L (no) | Anti-IGF1R-antistofformuleringer | |
CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
ECSP11011417A (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2008001201A1 (es) | Compuestos derivados de imidazol, triazol y/o piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension o insuficiencia cardiaca. | |
BRPI0909064A2 (pt) | revestimento hidrofílico |